The Diagnostic and Therapeutic Value of Anti CCP Antibodies and Double Stranded DNA in Rhupus Syndrome.

IF 0.7 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY Clinical laboratory Pub Date : 2024-09-01 DOI:10.7754/Clin.Lab.2024.240409

Xin Wang, Hong-Gang Sun, Pei-Feng Wang, Jia-Jia Wang, Jia-Ying Sun, Shu-Shan Zhao, Zhong-Ming Yu, Wen-Jing Fan, Xu-Yan Shen, Li-Qin He

{"title":"The Diagnostic and Therapeutic Value of Anti CCP Antibodies and Double Stranded DNA in Rhupus Syndrome.","authors":"Xin Wang, Hong-Gang Sun, Pei-Feng Wang, Jia-Jia Wang, Jia-Ying Sun, Shu-Shan Zhao, Zhong-Ming Yu, Wen-Jing Fan, Xu-Yan Shen, Li-Qin He","doi":"10.7754/Clin.Lab.2024.240409","DOIUrl":null,"url":null,"abstract":"Background: There have been only few reports on Rhupus syndrome with severe visceral involvement. Moreover, there was little consensus regarding its treatment. Belimumab is one of the options for treating this disease. For patients with clinical symptoms and elevated levels of anti CCP antibodies and anti-double stranded DNA antibodies, and it suggests Rhupus syndrome. After effective treatment, the decrease in levels of anti CCP antibodies and anti-double stranded DNA (ds-DNA) antibodies can effectively delay the progression of the disease and protect target organs.Methods: We used a chemiluminescence instrument, (Yahuilong; Shenzhen, China), to measure the changes in CCP and dsDNA before and after treatment.Results: Prior to treatment, the patient presented with symptoms of rheumatoid arthritis and systemic lupus erythematosus. Her laboratory tests showed dsDNA (214 IU/mL) and CCP level of ˃ 3,000 U/mL. After treatment with belimumab, the clinical symptoms were significantly relieved, and the patient's CCP IgG level decreased to 263.5 U/mL. A blood test found that her anti-dsDNA was negative.Conclusions: CCP and dsDNA can serve as indicators for the diagnosis and treatment of Rhupus syndrome.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.240409","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: There have been only few reports on Rhupus syndrome with severe visceral involvement. Moreover, there was little consensus regarding its treatment. Belimumab is one of the options for treating this disease. For patients with clinical symptoms and elevated levels of anti CCP antibodies and anti-double stranded DNA antibodies, and it suggests Rhupus syndrome. After effective treatment, the decrease in levels of anti CCP antibodies and anti-double stranded DNA (ds-DNA) antibodies can effectively delay the progression of the disease and protect target organs.

Methods: We used a chemiluminescence instrument, (Yahuilong; Shenzhen, China), to measure the changes in CCP and dsDNA before and after treatment.

Results: Prior to treatment, the patient presented with symptoms of rheumatoid arthritis and systemic lupus erythematosus. Her laboratory tests showed dsDNA (214 IU/mL) and CCP level of ˃ 3,000 U/mL. After treatment with belimumab, the clinical symptoms were significantly relieved, and the patient's CCP IgG level decreased to 263.5 U/mL. A blood test found that her anti-dsDNA was negative.

Conclusions: CCP and dsDNA can serve as indicators for the diagnosis and treatment of Rhupus syndrome.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

抗 CCP 抗体和双链 DNA 在红斑狼疮综合征中的诊断和治疗价值。

背景：关于严重内脏受累的红斑狼疮综合征的报道寥寥无几。此外，关于其治疗方法也鲜有共识。贝利木单抗是治疗这种疾病的选择之一。对于有临床症状且抗 CCP 抗体和抗双链 DNA 抗体水平升高的患者，提示其患有红斑狼疮综合征。经过有效治疗后，抗 CCP 抗体和抗双链 DNA（ds-DNA）抗体水平下降，可有效延缓病情发展，保护靶器官：方法：使用化学发光仪（亚辉龙，中国深圳）测量治疗前后CCP和dsDNA的变化：治疗前，患者有类风湿性关节炎和系统性红斑狼疮的症状。她的实验室检查结果显示dsDNA（214 IU/mL）和CCP水平为3000 U/mL。使用贝利木单抗治疗后，临床症状明显缓解，患者的 CCP IgG 水平降至 263.5 U/mL。血液检测发现，她的抗dsDNA呈阴性：结论：CCP 和 dsDNA 可作为诊断和治疗红斑狼疮综合征的指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical laboratory 医学-医学实验技术

CiteScore

1.50

自引率

0.00%

发文量

494

审稿时长

3 months

期刊介绍： Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.